Esperion Therapeutics, Inc (ESPR) saw its loss widen to $17.40 million, or $0.77 a share for the quarter ended Sep. 30, 2016. In the previous year period, the company reported a loss of $12.80 million, or $0.57 a share.
The company has not recorded any revenues for the current as well as previous quarter.
Operating loss for the quarter was $17.71 million, compared with an operating loss of $12.92 million in the previous year period.
“With the delivery of positive top-line results from the clinical studies of bempedoic acid in combination with high-dose statins, we will enroll patients with hypercholesterolemia on maximally tolerated lipid-modifying therapy, including patients on any statin at any dose, into our global pivotal Phase 3 program”, said Tim Mayleben, president and chief executive officer of Esperion Therapeutics. “While we continue to rapidly enroll patients into the global long-term safety study, we look forward to initiating the global pivotal Phase 3 LDL-C lowering efficacy studies and cardiovascular outcomes trial for bempedoic acid before year-end. With our available cash resources, we remain focused on delivering top-line results from our Phase 3 efficacy and long-term safety studies by mid-2018.”
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
